Small-Molecule Inhibition of PRMT5 Induces Translational Stress and p53 in JAK2V617F Mutant Myeloproliferative Neoplasms

被引：1

作者：

Sonderegger, Stefan ^{[1
]}

Cerruti, Loretta ^{[1
]}

Tremblay, Cedric ^{[1
]}

Toulmin, Emma ^{[1
]}

Saw, Jesslyn ^{[1
]}

Nebl, Tom ^{[2
]}

Hannan, Katherine M. ^{[3
]}

Lane, Steven W. ^{[4
]}

Falk, Hendrik ^{[5
]}

Unnikrishnan, Ashwin ^{[6
]}

Stupple, Paul ^{[7
]}

Street, Ian ^{[5
]}

Jane, Stephen ^{[8
]}

Altura, Rachel ^{[9
]}

Nicholson, Benjamin ^{[10
]}

Curtis, David J. ^{[1
,11
]}

机构：

[1] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia

[2] CSIRO, Biophys Grp, Parkville, Vic, Australia

[3] Australian Natl Univ, ACRF Dept Canc Biol & Therapeut, Canberra, ACT, Australia

[4] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia

[5] Cancer Therapeut CRC, Parkville, Vic, Australia

[6] UNSW Sydney, Sydney, NSW, Australia

[7] Monash Univ, Monash Inst Pharmaceut Sci, Parkville, Vic, Australia

[8] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia

[9] Merck Res Labs, Rahway, NJ USA

[10] Merck Res Labs, Boston, MA USA

[11] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-118406

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Calreticulin Mutation in JAK2V617F Negative Myeloproliferative Neoplasms - The Beaumont Experience
Sikdar, Soma
Prada, Anne
Crisan, Dominita
LABORATORY INVESTIGATION, 2015, 95 : 378A - 378A
[32] Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms
Ueda, Koki
Ikeda, Kazuhiko
Ogawa, Kazuei
Shichishima-Nakamura, Akiko
Shide, Kotaro
Shimoda, Kazuya
Hashimoto, Yuko
Mason, Philip J.
Bessler, Monica
Takeishi, Yasuchika
BLOOD, 2015, 126 (23)
[33] Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
Yonal-Hindilerden, Ipek
Daglar-Aday, Aynur
Akadam-Teker, Basak
Yilmaz, Ceylan
Nalcaci, Meliha
Yavuz, Akif Selim
Sargin, Deniz
JOURNAL OF BLOOD MEDICINE, 2015, 6 : 157 - 175
[34] Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
Guy, Alexandre
Danaee, Anicee
Paschalaki, Koralia
Boureau, Lisa
Riviere, Etienne
Etienne, Gabriel
Mansier, Olivier
Laffan, Michael
Sekhar, Mallika
James, Chloe
HEMASPHERE, 2020, 4 (03):
[35] Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Gery, Sigal
Cao, Qi
Gueller, Saskia
Xing, Hongtao
Tefferi, Ayalew
Koeffler, H. Phillip
JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 85 (06) : 957 - 965
[36] Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloproliferative neoplasms cells
刘贵敏
China Medical Abstracts(Internal Medicine), 2017, 34 (02) : 121 - 121
[37] IN JAK2V617F POSITIVE MYELOPROLIFERATIVE NEOPLASMS, BLEEDING RISK CORRELATES WITH ALLELE BURDEN
Bertozzi, I.
Cosi, E.
Santarossa, C.
Bogoni, G.
Fabris, F.
Randi, M. L.
HAEMATOLOGICA, 2017, 102 : 811 - 811
[38] Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation
Fan, Wenjuan
Cao, Weijie
Shi, Jianxiang
Gao, Fengcai
Wang, Meng
Xu, Linping
Wang, Fang
Li, Yingmei
Guo, Rong
Bian, Zhilei
Li, Wei
Jiang, Zhongxing
Ma, Wang
ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1745 - 1759
[39] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes, Raoul
Mesa, Ruben A.
LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
[40] Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
Guy, Alexandre
Helzy, Khalil
Mansier, Olivier
Bordet, Jean-Claude
Riviere, Etienne
Fiore, Mathieu
James, Chloe
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (02)

← 1 2 3 4 5 →